European Biosimilar Market Report 2022-2027: Expiration of Major Biologics Patents to Drive Market - ResearchAndMarkets.com

The "Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The biosimilar market in Europe reached a value of US$ 6,735 Million in 2021. Looking forward, the publisher expects the market to reach US$ 25,446 Million by 2027, exhibiting a CAGR of 22.8% during 2022-2027.

Drivers

Biosimilars are less expensive than their branded counterparts as they do not require extensive research and testing which saves both money and time; thereby lowering the costs. Moreover, they also have short marketing times as launching a biosimilar does not require extensive marketing as the safety and efficacy profile of their branded counterparts have already been established

Several blockbuster biologics are expected to lose their patent protection over the next 5 to 10 years. This expiration of patents and other intellectual property rights is expected to create huge opportunities for biosimilar manufacturers

The European population is ageing with around one fifth of the total EU population above 65 years of age. There has resulted in a significant increase in the burden of lifestyle diseases in the region. The prevalence of diseases such as diabetes, autoimmune diseases, oncology, etc. has been increasing rapidly in Europe. This is also expected to propel the market growth during the next few years

As a result of rising healthcare costs, governments across a number of European countries have formulated policies incentivising physicians, pharmacists and patients in favour of biosimilars over branded biologics

Key Market Segmentation:

Breakup by Country:

• Italy
• Germany
• United Kingdom
• France
• Spain
• Rest of Europe

Breakup by Molecule:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab

Breakup by Indication:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility

Breakup by Manufacturing Type:

• In-house Manufacturing
• Contract Manufacturing

Some of the leading players operating in the European biosimilars market include:

• Novartis
• Pfizer
• Teva
• Celltrion
• Samsung Bioepis
• Amgen
• Apotex
• Ratiopharm
• Mylan
• Merck Sharp & Dohme
• Eli Lilly
• Accord Healthcare Ltd
• Boehringer Ingelheim
• Hexal Ag
• Stada Arzneimittel Ag

This report provides a deep insight into the European biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the European biosimilars market in any manner

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Europe Biosimilars Market - Introduction

5 Europe Biosimilars Market

5.1 Market Overview

5.2 Historical and Current Market Trends

5.3 Impact of COVID-19

5.4 Market Breakup by Country

5.5 Market Breakup by Molecule

5.6 Market Breakup by Indication

5.7 Market Breakup by Manufacturing Type

5.8 Patent Landscape

5.9 Market Forecast

6 Market Breakup by Country

7 Market Breakup by Molecule

8 Market Breakup by Manufacturing Type

9 Market Breakup by Indication

10 European Biosimilar Market: SWOT Analysis

11 European Biosimilar Market: Value Chain Analysis

11.1 Characterizing the Existing Innovator Drug

11.2 Research and Development

11.2.1 Characterization of Biosimilars

11.2.2 Developing a Unique Cell Line

11.3 Product Development

11.3.1 Pre-Testing

11.3.2 Intermediary Clinical Testing (PK/PD)

11.3.3 Confirmatory Clinical Phase-III

11.4 Final Product Formulation

11.5 Marketing and Distribution

12 Porter's Five Forces Analysis

13 Price Analysis

13.1 Key Price Indicators

13.2 Price Trends

14 Requirements for Setting Up a Generic Drug Manufacturing Plant

14.1 Manufacturing Process

14.2 Raw Material Requirements

14.3 Raw Material Pictures

14.4 Land and Construction Requirements

14.5 Machinery and Infrastructure Requirements

14.6 Machinery Pictures

14.7 Plant Layout

14.8 Packaging Requirements

14.9 Utility Requirements

14.10 Manpower Requirements

For more information about this report visit https://www.researchandmarkets.com/r/dg3hn6

View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005167/en/